Comparison of Insulin Detemir, Insulin Aspart and Biphasic Insulin Aspart 30 With OAD Treatment in Type 2 Diabetes
A 36-month, Multi-centre, Open-label, Randomised, Parallel-group Trial Comparing the Safety, Efficacy and Durability of Adding a Basal Insulin Versus a Twice Daily Insulin Mixture Versus a Meal-time Rapid-Acting Insulin in Subjects With Type 2 Diabetes Inadequately Controlled on Therapy With Oral Agents, and Assessing the Requirement for More Complex Insulin Regimens to Achieve and Maintain Glycaemic Control, Their Efficacy and Durability
Sponsor: Novo Nordisk A/S
A PHASE3 clinical study on Diabetes and Diabetes Mellitus, Type 2, this trial is completed. The trial is conducted by Novo Nordisk A/S and has accumulated 8 data snapshots since 2004. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 3 earlier versions
-
May 2017 — Jun 2018 [monthly]
Completed PHASE3
-
Feb 2017 — May 2017 [monthly]
Completed PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE3
First recorded
Nov 2004
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Novo Nordisk A/S
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aberdeen, United Kingdom, Addlestone, United Kingdom, Airdrie, United Kingdom, Ashton-under-Lyne, United Kingdom, Ayr, United Kingdom, Belfast, United Kingdom, Berkshire, United Kingdom, Birmingham, United Kingdom, Bournemouth, United Kingdom, Bradford, United Kingdom and 40 more location s